FDA Releases Product-specific Bioequivalence Recommendations
Federal Register Notice: FDA is making available additional draft and revised draft product-specific bioequivalence (BE) recommendations on the design of BE studies to support ANDAs. These products include: albendazole, amlodipine besylate, betamethasone dipropionate, eluxadoline, and lenvatinib mesylate. To view this notice, click here.